MBOT at a glance
Insider buying, 7 days
FilingsNone filed this week
- Form 4s filed
- Nov 10 – Nov 16
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
MBOT price history
Loading recent earnings…
Investment thesis
What must happen next
MBOT's enlarged equity base will be sufficient to keep the company out of solvency-driven financing while it pursues the next meaningful business milestone.HoldingMateriality: High
future 10-Q/10-K filings show equity remains well above liabilities and no going-concern warning or rescue financing is disclosed. This is a load-bearing condition for Microbot Medical's investment case.
Watch: equity falls sharply toward prior low levels or the company discloses going-concern language, distressed financing, or creditor-driven constraints.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
future 10-Q/10-K filings show equity remains well above liabilities and no going-concern warning or rescue financing is disclosed.
Open source ↗Operating cash burn will begin to moderate rather than keep compounding from the FY2025 level.HoldingMateriality: High
trailing or full-year operating_cash_flow becomes less negative than FY2025's -$13.0 million. This is a load-bearing condition for Microbot Medical's investment case.
Watch: trailing or full-year operating_cash_flow becomes more negative than FY2025 or quarterly filings show burn accelerating.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
trailing or full-year operating_cash_flow becomes less negative than FY2025's -$13.0 million.
Open source ↗The FY2025 widening in operating losses will prove temporary, with spending translating into progress rather than a permanently higher loss base.HoldingMateriality: Medium
future trailing or annual operating_income loss narrows versus FY2025's -$14.7 million. This is a load-bearing condition for Microbot Medical's investment case.
Watch: future filings show the operating loss widening again or two straight quarters imply a worse annualized loss run-rate.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
future trailing or annual operating_income loss narrows versus FY2025's -$14.7 million.
Open source ↗Per-share losses will continue to improve, preserving upside for common shareholders despite ongoing development spending.HoldingMateriality: Medium
future eps_diluted loss narrows from FY2025's -$0.29 per share. This is a load-bearing condition for Microbot Medical's investment case.
Watch: future eps_diluted loss widens materially or financing actions cause per-share economics to deteriorate.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
future eps_diluted loss narrows from FY2025's -$0.29 per share.
Open source ↗MBOT will preserve its liability-light balance sheet instead of funding the program with material leverage or obligations.HoldingMateriality: Medium
future liabilities remain low relative to assets and no large debt or contingent obligation is disclosed. This is a load-bearing condition for Microbot Medical's investment case.
Watch: liabilities rise materially from the roughly $4 million level or new debt-like obligations become a major part of the capital structure.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
future liabilities remain low relative to assets and no large debt or contingent obligation is disclosed.
Open source ↗MBOT's surgical and medical instrument status will be validated by a concrete regulatory, clinical, commercial, or partnership milestone.HoldingMateriality: Medium
the company announces regulatory clearance or approval, first commercial use or sale, a customer contract, or a credible development partnership. This is a load-bearing condition for Microbot Medical's investment case.
Watch: the company discloses a program termination, major regulatory setback, or no tangible instrument-related milestone through the next annual report.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
the company announces regulatory clearance or approval, first commercial use or sale, a customer contract, or a credible development partnership.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
MBOT's enlarged equity base will be sufficient to keep the company out of solvency-driven financing while it pursues the next meaningful business milestone. This is a load-bearing condition for Microbot Medical's investment case.
Operating cash burn will begin to moderate rather than keep compounding from the FY2025 level. This is a load-bearing condition for Microbot Medical's investment case.
The FY2025 widening in operating losses will prove temporary, with spending translating into progress rather than a permanently higher loss base. This is a load-bearing condition for Microbot Medical's investment case.
Per-share losses will continue to improve, preserving upside for common shareholders despite ongoing development spending. This is a load-bearing condition for Microbot Medical's investment case.
MBOT will preserve its liability-light balance sheet instead of funding the program with material leverage or obligations. This is a load-bearing condition for Microbot Medical's investment case.
MBOT's surgical and medical instrument status will be validated by a concrete regulatory, clinical, commercial, or partnership milestone. This is a load-bearing condition for Microbot Medical's investment case.
All standing thesis claims
Original report summary
its surgical and medical instrument program produces regulatory or commercial proof before burn and financing pressure return, the upside case can work.
Bull case and bear case
Bull case and bear case for Microbot Medical
Where the evidence on Microbot Medical stands: Holding on the latest evidence (Nov 17, 2026). Of its 6 thesis points, 6 holding.
Bull case: what the evidence supports
MBOT's enlarged equity base will be sufficient to keep the company out of solvency-driven financing while it pursues the next meaningful business milestone.
Operating cash burn will begin to moderate rather than keep compounding from the FY2025 level.
The FY2025 widening in operating losses will prove temporary, with spending translating into progress rather than a permanently higher loss base.
Per-share losses will continue to improve, preserving upside for common shareholders despite ongoing development spending.
MBOT will preserve its liability-light balance sheet instead of funding the program with material leverage or obligations.
MBOT's surgical and medical instrument status will be validated by a concrete regulatory, clinical, commercial, or partnership milestone.
Bear case: what would count against it
equity falls sharply toward prior low levels or the company discloses going-concern language, distressed financing, or creditor-driven constraints.
trailing or full-year operating_cash_flow becomes more negative than FY2025 or quarterly filings show burn accelerating.
future filings show the operating loss widening again or two straight quarters imply a worse annualized loss run-rate.
Thesis-Break Engine
Thesis-break watch · Microbot Medical
Loading the break-condition record for Microbot Medical.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedRegulation FD disclosure.
Microbot Medical filed an SEC 8-K on 2026-11-16: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Microbot Medical filed an SEC 8-K on 2026-11-05: Regulation FD disclosure. It is a dated development that tests the current thesis.
- MixedRegulation FD disclosure.
Microbot Medical filed an SEC 8-K on 2026-10-27: Regulation FD disclosure. It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- equity falls sharply toward prior low levels or the company discloses going-concern language, distressed financing, or creditor-driven constraints.
- trailing or full-year operating_cash_flow becomes more negative than FY2025 or quarterly filings show burn accelerating.
- future filings show the operating loss widening again or two straight quarters imply a worse annualized loss run-rate.
- future eps_diluted loss widens materially or financing actions cause per-share economics to deteriorate.
- liabilities rise materially from the roughly $4 million level or new debt-like obligations become a major part of the capital structure.
- the company discloses a program termination, major regulatory setback, or no tangible instrument-related milestone through the next annual report.
MBOT news
Loading headlines…
Financial statements
MBOT income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.

